This open-label study investigated the extent to which 50-mg, once-daily ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, can reduce insulin requirements in type 2 diabetes mellitus patients who have progressed to basal insulin therapy.

After 24 weeks of treatment, ipragliflozin elicited a mean (standard deviation) change in basal insulin dose of − 6.6 ± 4.4 units/day, reflecting a mean percent change of − 29.87%, and one patient was able to stop insulin therapy entirely by Week 16.

Once-daily ipragliflozin safely and effectively reduced the dose of insulin necessary to maintain acceptable glycemic control.